Phaseline

Companies › Bambusa Therapeutics

Bambusa Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 6 registered trials: 6 Phase 1; Immunology, Respiratory; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BBT002–Phase 1Chronic Obstructive Pulmonary Disease (COPD); Chronic Obstructive Pulmonary Disease; Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)Dec 2026
BBT001–Phase 1Atopic Dermatitis; Chronic Spontaneous UrticariaFeb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07288554BBT002Phase 1Chronic Obstructive Pulmonary Disease (COPD)RespiratoryDec 2026
NCT06944925BBT002Phase 1Chronic Obstructive Pulmonary DiseaseRespiratoryJan 2027
NCT06808477BBT001Phase 1Atopic DermatitisImmunologyFeb 2027
NCT07717905BBT001Phase 1Chronic Spontaneous UrticariaImmunologyDec 2027
NCT07239947BBT001Phase 1Atopic DermatitisImmunologyDec 2027
NCT07436949BBT002Phase 1Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)RespiratoryDec 2027

From the company's SEC filings

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.